Background: Despite the ongoing developments in new biomaterials over the last decades, scientific research, the starting point for many medical applications, is still performed with human cells embedded in animal-derived materials. Animal-derived materials are not only regularly associated with the sacrifice of many animals, but the cultivation of human cells in combination with animal-origin products also does not reflect an ideal human cell environment. An alternative source of biomaterials is human placenta tissue which is globally available in large quantities. Objective: By using human placenta tissue, a so-called medical waste, THT Biomaterials reuses clinical material that would otherwise is discarded after birth to develop new human placenta-derived biomaterials. Methods: Human placenta extracellular proteins are isolated using enzymatic or non-enzymatic strategies allowing the obtention of large proteins quantities through a sustainable process. Around 500 mg per placenta can be obtained without additional invasive interventions. THT human placenta-derived biomaterials have been successfully used in cutting-edge life sciences applications such as 3D cell culture (stem cells, organoids), organ-on-a-chips, and 3D bioprinting replacing popular materials like mice tumor-based hydrogels and fetal calf serum (3Rs). Results: The human placenta-derived biomaterials have demonstrated a vast potential not only to replace animal materials in science but also to boost the translation of in vitro results into clinical applications. In prospect, THT Biomaterials based on a circular economy also aims to integrate these human biomaterials into clinical applications since they have a recognized potential as medical products. Conclusion: THT solution minimizes the lifecycle environmental impact of new products and can therefore contribute to a more sustainable future in light of the Sustainable Development Goals (SDGs) from the United Nations.